Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Transgene SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Transgene SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Transgene SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Transgene SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Transgene SA, Medical Devices Deals, 2012 to YTD 2018 10
Transgene SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Transgene SA, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Jennerex Biotherapeutics Raises US$21.6 Million In Venture Financing 13
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 14
Partnerships 16
BioInvent and Transgene Enter into Co-Development Agreement 16
Transgene and Randox Labs Enter into Agreement 17
Servier and Transgene Enters into Research Agreement 18
Bristol-Myers Squibb Enters into Research Agreement with Transgene 19
Transgene Enters into Agreement with Merck and Pfizer 20
Transgene Amends Agreement With SillaJen 21
Licensing Agreements 22
Elsalys Biotech Enters into Licensing Agreement with Transgene 22
Transgene Enters Into Licensing Agreement With Ascend Biopharma For TG1042 23
Equity Offering 24
Transgene Raises USD16.7 Million in Private Placement of Shares 24
Transgene Raises USD49 Million in Rights Offering of Shares 25
Transgene Completes Rights Offering Of Shares For US$62.4 Million 27
Transgene Completes Private Placement of Shares for up to USD27.44 Million 28
Asset Transactions 30
Advanced BioScience Labs Acquires Production Asset of Transgene 30
Acquisition 31
Tasly Pharma Acquires Remaining 50% Stake in Transgene-Tasly (Tianjin) BioPharma from Transgene for USD48 Million 31
SillaJen Completes Acquisition Of Jennerex For US$150 Million 32
Transgene Acquires 37% Stake in ElsaLys Biotech 34
Transgene SA – Key Competitors 35
Transgene SA – Key Employees 36
Transgene SA – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Affiliate 37
Joint Venture 38
Recent Developments 39
Financial Announcements 39
Apr 26, 2018: Transgene: €35.6 Million in Cash and Cash Equivalents as of March 31, 2018 39
Mar 21, 2018: Transgene to Announce Major Clinical Results in 2018 and Achieve Promising Progress on Its New Oncolytic Viruses 40
Apr 25, 2017: Transgene: €50.7 Million in Cash and Cash Equivalents as of March 31, 2017 46
Mar 20, 2017: Major Achievements in 2016 Validate Transgene’s Strategy and Provide Promising Outlook for 2017 47
Corporate Communications 51
Apr 19, 2017: Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors 51
Product News 52
10/26/2017: Transgene: First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma 52
Sep 21, 2017: Transgene Launches Invir.IO, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses 53
09/19/2017: Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers 54
Clinical Trials 56
Apr 18, 2018: Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018 56
Mar 15, 2018: Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018 57
Oct 30, 2017: Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017 58
Oct 23, 2017: TG1050 is Well Tolerated and Induces a Strong Specific Immune Response in Patients with Chronic Hepatitis B 59
Oct 17, 2017: Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B 60
Oct 12, 2017: Peer Reviewed Scientific Publications Highlight TG4010′s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors 61
Sep 11, 2017: Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer 62
Jul 24, 2017: Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus 63
Mar 30, 2017: Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC 64
Mar 13, 2017: First Patient Dosed in Phase 2 Trial Evaluating Transgenes TG4010 in Combination With Opdivo (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer 65
Other Significant Developments 66
Oct 19, 2017: Transgene: Third Quarter Marked by Progress in Clinical Development and Research 66
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
Transgene SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Transgene SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Transgene SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Transgene SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Transgene SA, Deals By Therapy Area, 2012 to YTD 2018 9
Transgene SA, Medical Devices Deals, 2012 to YTD 2018 10
Transgene SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Jennerex Biotherapeutics Raises US$21.6 Million In Venture Financing 13
ElsaLys Biotech Raises US$2.7 Million In First Round Of Financing 14
BioInvent and Transgene Enter into Co-Development Agreement 16
Transgene and Randox Labs Enter into Agreement 17
Servier and Transgene Enters into Research Agreement 18
Bristol-Myers Squibb Enters into Research Agreement with Transgene 19
Transgene Enters into Agreement with Merck and Pfizer 20
Transgene Amends Agreement With SillaJen 21
Elsalys Biotech Enters into Licensing Agreement with Transgene 22
Transgene Enters Into Licensing Agreement With Ascend Biopharma For TG1042 23
Transgene Raises USD16.7 Million in Private Placement of Shares 24
Transgene Raises USD49 Million in Rights Offering of Shares 25
Transgene Completes Rights Offering Of Shares For US$62.4 Million 27
Transgene Completes Private Placement of Shares for up to USD27.44 Million 28
Advanced BioScience Labs Acquires Production Asset of Transgene 30
Tasly Pharma Acquires Remaining 50% Stake in Transgene-Tasly (Tianjin) BioPharma from Transgene for USD48 Million 31
SillaJen Completes Acquisition Of Jennerex For US$150 Million 32
Transgene Acquires 37% Stake in ElsaLys Biotech 34
Transgene SA, Key Competitors 35
Transgene SA, Key Employees 36
Transgene SA, Other Locations 37
Transgene SA, Subsidiaries 37
Transgene SA, Affiliate 37
Transgene SA, Joint Venture 38
List of Figures
Transgene SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Transgene SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Transgene SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Transgene SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Transgene SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Transgene SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Transgene SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Transgene SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Transgene SA, Medical Devices Deals, 2012 to YTD 2018 10
